Scholarlink

<p>Upadacitinib is an oral selective Janus kinase 1 (JAK1) inhibitor that targets specific pathways in immune-inflammatory responses. It is increasingly being utilized in the treatment of certain autoimmune diseases. There have been reports of solid tumors and thromboembolic events associated with upadacitinib use. However, to date, no reports have linked upadacitinib therapy to leukemia. Here, we present the first documented case of acute promyelocytic leukemia (APL) complicated by lower extremity venous thrombosis following upadacitinib treatment for vitiligo. The patient maintained normal or mildly reduced platelet counts throughout the clinical course, with no significant coagulation abnormalities requiring component blood transfusions. The patient achieved complete remission following standard induction therapy with all-trans retinoic acid and arsenic trioxide, with an uneventful treatment course. Notably, this clinical presentation markedly differs from typical APL cases, demonstrating unique biological characteristics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acute Promyelocytic Leukemia Accompanied with Venous Thrombosis Subsequent to Upadacitinib Therapy

  • 期刊论文

  • 发表日期：

    2025年10月22日

查看全文
  • Hui Wang,
  • Zhan Su,
  • Fuli Fan,
  • Xiaolin Ma,
  • Yingshuai Wang,
  • Wei Wang

摘要

Upadacitinib is an oral selective Janus kinase 1 (JAK1) inhibitor that targets specific pathways in immune-inflammatory responses. It is increasingly being utilized in the treatment of certain autoimmune diseases. There have been reports of solid tumors and thromboembolic events associated with upadacitinib use. However, to date, no reports have linked upadacitinib therapy to leukemia. Here, we present the first documented case of acute promyelocytic leukemia (APL) complicated by lower extremity venous thrombosis following upadacitinib treatment for vitiligo. The patient maintained normal or mildly reduced platelet counts throughout the clinical course, with no significant coagulation abnormalities requiring component blood transfusions. The patient achieved complete remission following standard induction therapy with all-trans retinoic acid and arsenic trioxide, with an uneventful treatment course. Notably, this clinical presentation markedly differs from typical APL cases, demonstrating unique biological characteristics.